Repression of RUNX1 Activity by EVI1: A New Role of EVI1 in Leukemogenesis
Authors:
- 15 June 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (12) , 5658-5666
Abstract
Recurring chromosomal translocations observed in human leukemia often result in the expression of fusion proteins that are DNA-binding transcription factors. These altered proteins acquire new dimerization properties that result in the assembly of inappropriate multimeric transcription complexes that deregulate hematopoietic programs and induce leukemogenesis. Recently, we reported that the fusion protein AML1/MDS1/EVI1 (AME), a product of a t(3;21)(q26;q22) associated with chronic myelogenous leukemia and acute myelogenous leukemia, displays a complex pattern of self-interaction. Here, we show that the 8th zinc finger motif of MDS1/EVI1 is an oligomerization domain involved not only in interaction of AME with itself but also in interactions with the parental proteins, RUNX1 and MDS1/EVI1, from which AME is generated. Because the 8th zinc finger motif is also present in the oncoprotein EVI1, we have evaluated the effects of the interaction between RUNX1 and EVI1 in vitro and in vivo. We found that in vitro, this interaction alters the ability of RUNX1 to bind to DNA and to regulate a reporter gene, whereas in vivo, the expression of the isolated 8th zinc finger motif of EVI1 is sufficient to block the granulocyte colony-stimulating factor–induced differentiation of 32Dcl3 cells, leading to cell death. As EVI1 is not detected in normal bone marrow cells, these data suggest that its inappropriate expression could contribute to hematopoietic transformation in part by a new mechanism that involves EVI1 association with key hematopoietic regulators, leading to their functional impairment. [Cancer Res 2007;67(12):5658–66]Keywords
All Related Versions
This publication has 19 references indexed in Scilit:
- Point Mutations in Two EVI1 Zn Fingers Abolish EVI1-GATA1 Interaction and Allow Erythroid Differentiation of Murine Bone Marrow CellsMolecular and Cellular Biology, 2006
- t(3;21)(q26;q22) in myeloid leukemiaCancer, 2006
- EVI1 and hematopoietic disorders: History and perspectivesGene, 2006
- EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangementsGenes, Chromosomes and Cancer, 2005
- Normal and transforming functions of RUNX1: A perspectiveJournal of Cellular Physiology, 2005
- SUV39H1 interacts with AML1 and abrogates AML1 transactivity. AML1 is methylated in vivoOncogene, 2003
- Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemiaGenes, Chromosomes and Cancer, 2002
- The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cellsOncogene, 2002
- Interaction of EVI1 with cAMP-responsive Element-binding Protein-binding Protein (CBP) and p300/CBP-associated Factor (P/CAF) Results in Reversible Acetylation of EVI1 and in Co-localization in Nuclear SpecklesJournal of Biological Chemistry, 2001
- MDS1/EVI1 enhances TGF-β1 signaling and strengthens its growth-inhibitory effect, but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-β1Leukemia, 1999